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It therefore seems logical to intervene
in the C5a–C5a receptor interaction in
patients with AAV. Indeed, a clinical
trial evaluating the safety and efficacy
of an inhibitor of the C5a receptor
(CCX168), a small molecule that is
orally administered, has been started in
patients with ANCA-associated renal
vasculitis (ClinicalTrials.gov identifier
NCT01363388). The results of this trial,
which are eagerly awaited, should
demonstrate whether intervention in
the complement system will become an
essential step in the early treatment of
patients with life-threatening AAV.
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Access to kidney transplantation
in Australia: does equal mean
equitable?
Fergus J. Caskey1 and Rommel Ravanan1
Sociodemographic gradients have been widely reported in end-stage
renal disease treatment, as in the general population. So should we be
relieved by the report from Grace et al. of no such gradient in access to
deceased donor kidney transplantation in Australia? Although the
authors have adjusted for the ‘competing risk’ of living kidney donor
transplantation, which is higher in higher socioeconomic groups, it feels
a little early to be reassured.
Kidney International (2012) 83, 18–20. doi:10.1038/ki.2012.372
Kidney transplantation offers patients
with end-stage renal disease the greatest
survival and quality-of-life opportunities,
with the best results observed in those
receiving kidneys from living donors.
In order for a patient to receive a kidney
transplant, a number of steps must be
successfully completed (Figure 1).1 First,
the potential recipient must receive
accurate, balanced information about
the treatment options available. Al-
though this sounds straightforward, it
relies on the treating clinician having the
communication skills to raise the topic in
a timely manner, provide appropriate
information about the various treatment
options, and identify potential barriers to
transplantation for that individual. None
of this can happen until the patient has
been referred to a nephrologist and, in
some settings, until he or she have been
referred by that nephrologist to a
transplant physician or surgeon. The
various components of the transplant
assessment need to be completed, each
of which introduces delays as well as
direct and indirect costs to the recipient.
Although many national organizations
have guidelines on suitability for kidney
transplantation, these are largely based
on expert opinion, and the final decision
remains highly subjective. Once the
patient is on the waiting list, organ
allocation protocols largely take over.
Living kidney donor (LKD) trans-
plantation introduces further potential
barriers, costs, and delays. Balanced,
informed information about the risks
and benefits of all options needs to
reach potential donors, who have to be
healthy enough to donate and finan-
cially secure enough not to be dis-
suaded by the threat to their income,
job, or future health-care costs.
It is in this context that we read the
interesting report from the Australia
and New Zealand Dialysis and Trans-
plant Registry (ANZDATA) on access to
kidney transplantation in Australia
(Grace et al.,2 this issue). Studying all
patients commencing renal replace-
ment therapy in Australia from 2000
to 2010 (n¼ 21,190), Grace et al. report
93% higher preemptive transplantation
rates for people living in the most
affluent areas. All preemptive trans-
plants were the result of LKD trans-
plantation, and this higher rate of LKD
transplantation persisted on to renal
replacement therapy, with those from
affluent areas having a 34% increased
chance of receiving an LKD transplant
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compared with those from the most
socially deprived areas. Remarkably, no
difference was observed in rates of
deceased donor kidney transplantation
across the social deprivation gradient.
Higher rates of LKD transplantation
among more affluent people have been
reported previously in the United
Kingdom and the United States, but
with similar patterns observed in access
to deceased donor transplantation.3,4 Is
increased access of affluent people to
deceased donor transplantation in
Australia being cancelled out by ‘in-
formed censoring,’ with more difficult-
to-transplant cases from affluent areas
being left on the deceased donor
waiting list? Such ‘cherry picking’ by
the LKD program would mean that the
now equal transplant rates in the
deceased donor program in fact still
represent increased access to transplan-
tation for the socially affluent. That
said, the authors have applied the most
appropriate statistical methods—
competing-risk proportional hazards—
to take account of this potential bias.
Whether statistics can ever fully adjust
for such effects in observational data is a
moot point, and it is notable that the
results from the competing-risk ap-
proach differ little, in a sensitivity
analysis, from those of the more familiar
Cox model.
It is also worth remembering that
socioeconomic status has been mea-
sured at the area, rather than the
individual, level. As well as the slightly
different implications for the interpre-
tation of the results—differences may
be the result of structure and organiza-
tion of the area rather than the
individual’s poverty—there is also the
risk of ecological fallacy, that is, that
the average characteristics of the area do
not truly reflect those of the individual.
As the authors point out, postcode
areas in Australia are relatively small in
population size, but if anything, this
effect is likely to have attenuated any
inequalities in access to transplantation
according to socioeconomic status.
Geographical variation in transplant
rates has been recognized in North
America, Europe, and Australia for
some time.5 Concerns were initially
raised about the allocation of organs
to patients already on the transplant
waiting list, and indeed this remains a
hot topic in a number of countries with
concerns that multiorgan transplants,
especially liver–kidney and pancreas–
kidney, might be distorting allocation
of kidneys. International comparisons6
have also highlighted marked differ-
ences in access to the waiting list and
access to LKD transplantation between
countries. Unfortunately, it was not
possible to link waiting-list data with
the historical ANZDATA included in
the analysis by Grace et al.2 Given the
inequalities in health and access to
health care that exist in most studied
general populations, it would perhaps
be more surprising if inequalities did
not exist in access to transplantation.
The question is whether these inequa-
lities represent inequities.
In the United Kingdom, when gov-
ernment invested to reduce premature
mortality rates, the gap between rich
and poor actually increased, though
there were improvements across the
board; incremental benefits tend to be
smallest in those with greatest need.7
In this regard it is worth noting that in
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Figure 1 | Patient decision making to gain access to kidney transplantation. (Reprinted
with permission from Gordon et al.1)
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Grace et al.’s analysis, the profile of
LKD relationships and the reduced
chance of receiving an LKD transplant
associated with socioeconomic status
remained constant between states and
across time despite marked differences
between states and increases over time
in absolute LKD rates. Perhaps one
reason for this is the relatively low
percentage of patients in Australia who
are activated on the transplant waiting
list compared with other countries—
18% of dialysis patients younger than
65 in Australia compared with 49% in
France, 48% in the United Kingdom,
and 33% in the United States.8
There are also some noteworthy high-
achieving transplant program models
around the world. In Norway, a very
active LKD program makes it possible for
nearly 90% of patients younger than 65
on dialysis to access the deceased donor
transplant waiting list, and almost all of
these receive a transplant within 4 years
of starting dialysis.6 Iran has also achieved
remarkable transplant access through
LKD transplantation, in this case with a
government initiative regulating and
financially supporting living unrelated
donation.9 Although such an approach
is not without controversy, its effect has
been to develop skills in a generation of
surgeons and enable the setting up of a
very promising deceased donor scheme.9
Although medical factors will always
play a role, the importance of psycho-
logical, social, and cultural factors in
determining differences in rates of trans-
plantation is increasingly being recog-
nized,10 particularly through the patient’s
interpretation and assessment of risk
associated with transplantation and how
it compares with the status quo of
dialysis.1 It has even been suggested that
socioeconomic status no longer associates
with reduced access once differences in
health, functional status, and psycho-
social factors such as ‘attitudes toward
treatment’ have been accounted for.11 If
we are to reduce inequity in access to
transplantation, we must first understand
the educational, psychological, and social
milieu of specific patients at specific
times. Some of these factors may have
more potential for modification than the
patient demographics and comorbidity.
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The OSCAR for cardiovascular
disease prevention in chronic
kidney disease goes to blood
pressure control
Alexandros Briasoulis1 and George L. Bakris1
Nephropathy progression is slowed and cardiovascular events reduced
in patients with stage 3 or higher chronic kidney disease when blood
pressure is controlled using combinations of renin–angiotensin system
(RAS) blockers with dihydropyridine calcium channel blockers or diuretics.
We discuss a trial comparing high-dose RAS blockade with lower-dose
RAS blockade combined with a dihydropyridine calcium channel blocker.
The primary outcome was cardiovascular events. The combination
group had better blood pressure control and fewer total events.
Kidney International (2012) 83, 20–22. doi:10.1038/ki.2012.364
Cardiovascular disease is the leading cause
of mortality in patients with chronic
kidney disease (CKD), stage 3 or high-
er; their risk increases as estimated
glomerular filtration rate (eGFR) falls.
Recently, stage 3 or higher CKD was
acknowledged as contributing more
risk for all-cause mortality than prior
myocardial infarction or diabetes.1
Almost all people with CKD, stage 3
or higher, require two or more medi-
cations to help achieve guideline
recommended blood pressure goals.2
Before the completion of the Avoiding
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